Physician
The Finley Hospital
The Finley Hospital was paid $14.07M by Medicaid between Jan 2018 and Dec 2024, across 109 billing codes. Its largest line is 99284, emergency room visit (serious) — 35% of everything it billed.
33Billing provider infoTHE FINLEY HOSPITAL
DUBUQUE, IA 52001
DUBUQUE, IA 52001
33aNPI1942392600assigned 09/29/2006
33bProvider typeEmergency Medicine Physician
28Total paid$14.07M
24GClaims243,211
24DCodes billed109
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Iowa
Rank by total paid#1 of 77
Median peer was paid$99K
This provider vs. median142×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,374 | $1.88M | |
| 2019 | 41,024 | $2.19M | |
| 2020 | 32,184 | $1.81M | |
| 2021 | 36,599 | $2.36M | |
| 2022 | 44,059 | $2.68M | |
| 2023 | 38,122 | $2.15M | |
| 2024incomplete | 17,849 | $995K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 19,516 | 18,286 | $4.86M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 21,988 | 20,883 | $3.56M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 5,181 | 4,782 | $1.70M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.4% | 8,227 | 7,503 | $1.04M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.7% | 44,613 | 41,880 | $517K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.8% | 7,851 | 7,050 | $399K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.7% | 6,891 | 6,311 | $373K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.2% | 1,038 | 1,000 | $314K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.7% | 4,124 | 3,894 | $239K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.3% | 1,662 | 1,587 | $181K |
| 0240U | 1.2% | 1,295 | 1,263 | $172K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,409 | 2,248 | $133K |
97 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 749 | $98K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,563 | $64K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 807 | $63K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,090 | $59K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,089 | $46K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 411 | $39K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 262 | $37K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 245 | $33K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,985 | $24K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 94 | $20K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 145 | $14K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 398 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 289 | $9K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 42 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,901 | $7K |
| 62323 | <1% | 27 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 289 | $6K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 138 | $5K |
| 80053 | Comprehensive metabolic panel | <1% | 14,922 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 340 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,335 | $4K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,620 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $3K |
| 0353U | <1% | 124 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 100 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,395 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,650 | $2K |
| 59025 | Fetal non-stress test | <1% | 13 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 44 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 125 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 426 | $882.48 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 209 | $807.43 |
| 93017 | <1% | 25 | $531.63 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 519 | $488.82 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 29 | $466.76 |
| 80061 | Lipid panel | <1% | 37 | $385.11 |
| 86140 | <1% | 2,470 | $271.52 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $251.68 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 931 | $198.97 |
| 81000 | <1% | 4,265 | $178.79 | |
| 86780 | <1% | 13 | $150.96 | |
| 86803 | <1% | 13 | $149.16 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 507 | $117.45 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 248 | $112.01 |
| 87340 | <1% | 13 | $107.91 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 871 | $75.70 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,462 | $73.56 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 465 | $60.12 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,898 | $52.34 |
| 83690 | <1% | 3,693 | $49.17 | |
| 86850 | <1% | 12 | $48.74 | |
| 82950 | <1% | 14 | $45.10 | |
| 87486 | <1% | 204 | $41.16 | |
| 87581 | <1% | 204 | $41.16 | |
| 81025 | <1% | 891 | $25.33 | |
| 87081 | <1% | 660 | $23.80 | |
| 83605 | <1% | 1,337 | $19.91 | |
| 81001 | <1% | 3,571 | $15.20 | |
| 84703 | <1% | 1,228 | $14.66 | |
| 84484 | <1% | 2,864 | $13.25 | |
| 82010 | <1% | 562 | $11.40 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 513 | $11.33 |
| 85610 | <1% | 1,251 | $5.16 | |
| 81003 | <1% | 940 | $2.14 | |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 878 | $1.52 |
| 82962 | <1% | 68 | $0.23 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 907 | $0.00 |
| 85379 | 0% | 494 | $0.00 | |
| 87040 | 0% | 601 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 97 | $0.00 |
| 82803 | 0% | 533 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 156 | $0.00 |
| 83735 | 0% | 355 | $0.00 | |
| 87077 | 0% | 49 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 250 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 152 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 227 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 13 | $0.00 |
| 81015 | 0% | 27 | $0.00 | |
| 83880 | 0% | 250 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 45 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 49 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 87 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 12 | $0.00 |
| 85730 | 0% | 14 | $0.00 | |
| 82077 | 0% | 12 | $0.00 | |
| 87631 | 0% | 251 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 94 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 467 | $0.00 |
| 84145 | 0% | 323 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 135 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 28 | $0.00 |
| 85380 | 0% | 197 | $0.00 | |
| J0595 | Injection, butorphanol tartrate, 1 mg | 0% | 25 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 29 | $0.00 |
| 82272 | 0% | 14 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAVENS, JENNIFER (MARKET PRESIDENT)